Clone of_PULSE: The Weight is Over: Direct Acting Oral Anticoagulants (DOACs) in Obesity - March 17, 2021
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Target Audience
Pharmacist
Learning Objectives
1) Describe pharmacokinetic changes that occur when DOACs (apixaban and rivaroxaban) are used in obese patients
2) Review the current guideline recommendations for the use of DOACs in obesity
3) Discuss comparative studies that assess the use of DOACs in obese patients
4) Identify appropriate DOAC treatment options for an obese patient
New medications and new guidelines are constantly being released. Pharmacists need a mechanism to keep up with these new medications and guidelines.
Megha Patel, PharmD
PGY1 Pharmacy Resident
UPMC Shadyside
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team
Available Credit
- 1.00 ACPE PharmacyThe UPMC Center for Continuing Education in the Health Sciences is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a Provider of continuing pharmacy education.